B+
Bull case
30%
Probability
Target price
$20.00
+58.1% vs current
AMRX
AmnealBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$16.80
+32.8% vs current
B-
Bear case
20%
Probability
Target price
$9.50
-24.9% vs current
AI sentiment snapshot
Latest data as of 2026-05-27
Recent news sentiment (30D)
+0.6
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+78.2
Score
AI commentary
Primary-source tone is constructive because Q1 results reaffirmed the raised FY2026 outlook and the Kashiv transaction adds longer-term biosimilar optionality. Confidence stays moderate rather than high because the packet does not include a fresh analyst revision set or confirmed post-print price reaction, and social context is absent, so this remains a monitoring-style positive thesis.
RankAlpha Sentiment Codex - 2026-05-27
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-07catalystQ1 2026 results kept the raised FY2026 outlook intactMedium impact
Amneal reported Q1 2026 net revenue of $723 million, adjusted EBITDA of $202 million, and adjusted diluted EPS of $0.27, and management reaffirmed the previously raised FY2026 standalone guidance. Specialty growth was led by CREXONT and BREKIYA. [#10-Q-2026-05-07]
2026-12-31eventKashiv acquisition could expand the biosimilars platform if closing stays on trackHigh impact
Amneal agreed to acquire 100% of Kashiv BioSciences for $375 million of cash and $375 million of equity at closing, plus up to $350 million of milestone- and royalty-linked consideration, with a targeted close in the second half of 2026. The main swing factors are regulatory approval, integration, and whether the expected biosimilar platform benefits show up on schedule.
2026-12-31catalystSpecialty launch cadence can keep improving the earnings mixHigh impact
The company’s Q1 disclosure still pointed to Specialty revenue growth from CREXONT, BREKIYA, and UNITHROID, while Affordable Medicines also grew. If launch cadence and category demand persist, the mix should support multi-quarter earnings power. [#10-Q-2026-05-07]
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-27 • Updated nightlySource: Internal modelMethodology